Nisha Acharya, MD
Enriched profileElizabeth C. Proctor Distinguished Professor, F.I. Proctor Foundation and Departments of Ophthalmology and Epidemiology & Biostatistics; Director, Uveitis and Ocular Inflammatory Disease Service · University of California, San Francisco
Nisha Acharya is Elizabeth C. Proctor Distinguished Professor, F.I. Proctor Foundation and Departments of Ophthalmology and Epidemiology & Biostatistics; Director, Uveitis and Ocular Inflammatory Disease Service at University of California, San Francisco. OpenAlex indexes 277 publications with 9,379 citations (h-index 54); ClinicalTrials.gov lists 11 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Ophthalmology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Nisha Acharya, MD, is Elizabeth C. Proctor Distinguished Professor, F.I. Proctor Foundation and Departments of Ophthalmology and Epidemiology & Biostatistics at University of California, San Francisco (F.I. Proctor Foundation / Department of Ophthalmology). The public record shows 277 publications with 9,379 citations (h-index 54), centered on Ocular Diseases and Behçet’s Syndrome, Ocular Infections and Treatments, Ocular Surface and Contact Lens. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 3 companies, 6 NIH-funded awards (2007–2026).
- Most recent indexed publication: 2025 · BMJ open
- Top research focus: Ocular Diseases and Behçet’s Syndrome
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 3 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 146.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Adalimumab Dose Adjustment for Pediatric Uveitis Treatment Trial
Sponsor: Nisha Acharya
- Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases
Sponsor: University of California, San Francisco
- Adalimumab in JIA-associated Uveitis Stopping Trial
Sponsor: Nisha Acharya
Industry payments
Updated 27 Aug 2026
3 companies reported payments to CMS in program years 2022–2025. These are public disclosures, not judgments. The latest:
- Genentech USA, Inc.Program year202510 payments$14,953openpaymentsdata.cms.gov ↗
- Genentech, Inc.Program year20252 payments
- Genentech, Inc.Program year20244 payments$11,486openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
100%Corticosteroids, plain100%Durezol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
6 NIH research awards on record, funded 2007–2026 per NIH RePORTER. The latest:
- Adalimumab Dose Adjustment for Pediatric uveitis Treatment (ADAPT) Trial
University of California, San Francisco
FY2026$1,655,047UG1EY038172 - The Impact of the Herpes Zoster Vaccine on Herpes Zoster Ophthalmicus
University of California, San Francisco
FY2026$606,466R01EY028739 - Adalimumab Dose Adjustment for Pediatric uveitis Treatment (ADAPT) Trial
University of California, San Francisco
FY2026$58,047UG1EY038172
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Comparison of CD4 Counts with Mycophenolate Mofetil versus Methotrexate from the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial.
Ocular immunology and inflammation
Clinical Trial2022
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03The Mycotic Ulcer Treatment TrialArticle346 citations2012
- 04
- 05Incidence and Prevalence of UveitisArticle286 citations2013
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/cv/nisha-acharya-md-2
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- YouTube
retinapodcast.com/episodes/2020/7/13/episode-246-uveitis-training-and-the-fast-study-with-dr-nisha-acharya
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →retinapodcast.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗
- Board Certified
Ophthalmology, American Board of Ophthalmology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucsfhealth.org ↗
Editorial & leadership roles
journal and society appointments- Director
Uveitis and Ocular Inflammatory Disease Service, F.I. Proctor Foundation, UCSF
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ophthalmology.ucsf.edu ↗ - Director
Uveitis Fellowship, F.I. Proctor Foundation, UCSF
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.ucsf.edu ↗ - Protocol co-chair
Multicenter Uveitis Steroid Treatment (MUST) trial group macular edema trial
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ophthalmology.ucsf.edu ↗
Awards & honors
honors on the public record- Mildred Weisenfeld Award (ARVO Achievement Award)
Association for Research in Vision and Ophthalmology, 2026 …
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ophthalmology.ucsf.edu ↗ - 22nd Annual Faculty Research Lectureship in Clinical Science
UCSF, lecture titled 'Small Field, Big Data: Advancing Evidence for Ocular Inflammatory Diseases,' scheduled March 5
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ophthalmology.ucsf.edu ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ophthalmology.ucsf.edu ↗
Media & interviews
press, podcasts and appearances- Feature interview: 'ARVO 2026: Mildred Weisenfeld Award winner Nisha Acharya
MD, on big data, trials, and vision preservation,' Ophthalmology Times
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ophthalmologytimes.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →proctoruveitis.ucsf.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Kristine Yaffe, MD
University of California, San Francisco
Peter Carroll, MD
University of California, San Francisco
Mitchel Berger, MD
University of California, San Francisco
Elyse Foster, MD
University of California, San Francisco